Wenger Plattner advised Bachem on the terms of the collaboration agreement and regarding aspects of SIX Listing Rules.
On 26 April 2022, Bachem (SIX: BANB) announced a strategic collaboration with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules. Under this collaboration, Bachem will support the implementation of Lilly’s novel oligonucleotide manufacturing technology with its engineering infrastructure and expertise and provide R&D and production capacity at its Bubendorf (BL) site for the development and manufacture of GMP-grade material for Lilly’s oligonucleotide-based investigational medicines. Manufacturing commitments by Lilly extend over a term of 7 years, with annual order volume potential of around CHF 100m.
Wenger Plattner (Dr. Tobias Meili) advised Bachem on the terms of the collaboration agreement and regarding aspects of SIX Listing Rules.